159 related articles for article (PubMed ID: 26696550)
1. TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.
Zha Y; Gan P; Liu Q; Yao Q
Arch Med Res; 2016 Jan; 47(1):13-8. PubMed ID: 26696550
[TBL] [Abstract][Full Text] [Related]
2. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
3. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
Wang S; Chen L; Zhao Q; Rong H; Wang M; Gong W; Zhou J; Wu D; Zhang Z
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1073-82. PubMed ID: 23423487
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of expression of Kit67, p53, TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy.
Zha Y; Cun Y; Zhang Q; Li Y; Tan J
Hepatogastroenterology; 2012; 59(117):1327-32. PubMed ID: 22534478
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; He Q; Hua D; Mao Y; Li Y; Shen L
Clin Transl Oncol; 2013 Aug; 15(8):619-25. PubMed ID: 23263912
[TBL] [Abstract][Full Text] [Related]
6. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.
Malisic E; Jankovic R; Jakovljevic K; Radulovic S
J BUON; 2011; 16(4):701-7. PubMed ID: 22331725
[TBL] [Abstract][Full Text] [Related]
7. Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation.
Lu M; Wang T; Wang J
Int J Clin Pharmacol Ther; 2016 Sep; 54(9):693-7. PubMed ID: 27390051
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
9. Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms.
Ohmori Y; Nomura T; Fukushima N; Takahashi F; Iwaya T; Koeda K; Nishizuka SS;
J Surg Oncol; 2019 Dec; 120(7):1154-1161. PubMed ID: 31578743
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Yu J; Gao J; Lu Z; Li Y; Shen L
Med Oncol; 2012 Dec; 29(5):3029-34. PubMed ID: 22766748
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.
Lu Z; Zhang X; Liu W; Liu T; Hu B; Li W; Fan Q; Xu J; Xu N; Bai Y; Pan Y; Xu Q; Bai W; Xia L; Gao Y; Wang W; Shu Y; Shen L
Gastric Cancer; 2018 Sep; 21(5):782-791. PubMed ID: 29488121
[TBL] [Abstract][Full Text] [Related]
12. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; Lu M; Yu JW; Li YY; Shen L
BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
[TBL] [Abstract][Full Text] [Related]
13. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
14. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy.
Chang H; Rha SY; Jeung HC; Im CK; Noh SH; Kim JJ; Chung HC
Oncol Rep; 2010 Jan; 23(1):271-8. PubMed ID: 19956892
[TBL] [Abstract][Full Text] [Related]
15. Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Deenen MJ; Meulendijks D; Boot H; Legdeur MC; Beijnen JH; Schellens JH; Cats A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1285-95. PubMed ID: 26499900
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma.
Zhang ZW; Laurence NJ; Hollowood A; Newcomb P; Moorghen M; Gupta J; Feakins R; Farthing MJ; Alderson D; Holly J
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):131-5. PubMed ID: 14734461
[TBL] [Abstract][Full Text] [Related]
17. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
18. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
19. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
[TBL] [Abstract][Full Text] [Related]
20. [TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela].
Cañas M; Morán Y; Camargo ME; Rivero MB; Bohórquez A; Villegas V; Ramírez E; Rendón Y; Suárez A; Morales L; Useche E; Salazar S; Zambrano A; Ramírez A; Valderrama E; Briceño Z; Chiurillo MA
Invest Clin; 2009 Jun; 50(2):153-61. PubMed ID: 19662811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
